-
(2R,3R)-2,3-dihydroxybutanedioic acid; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-1,2,3,4-tetrahydroquinazoline-2,4-dione
-
ChemBase ID:
132715
-
Molecular Formular:
C26H28FN3O9
-
Molecular Mass:
545.5136232
-
Monoisotopic Mass:
545.18095771
-
SMILES and InChIs
SMILES:
c1ccc2c(c1)c(=O)n(c(=O)[nH]2)CCN1CCC(CC1)C(=O)c1ccc(cc1)F.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
Canonical SMILES:
OC(=O)[C@@H]([C@H](C(=O)O)O)O.Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2
InChI:
InChI=1S/C22H22FN3O3.C4H6O6/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29;5-1(3(7)8)2(6)4(9)10/h1-8,16H,9-14H2,(H,24,29);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
InChIKey:
KMTLTEVOQLMYRS-LREBCSMRSA-N
-
Cite this record
CBID:132715 http://www.chembase.cn/molecule-132715.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(2R,3R)-2,3-dihydroxybutanedioic acid; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-1,2,3,4-tetrahydroquinazoline-2,4-dione
|
|
|
IUPAC Traditional name
|
L(+)-tartaric acid; ketanserin
|
|
|
Synonyms
|
3-(2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl)-2,4(1H,3H)-quinazolinedione (+)-tartrate salt
|
R 41468 (+)-tartrate salt
|
Ketanserin (+)-tartrate salt
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
11.424021
|
H Acceptors
|
4
|
H Donor
|
1
|
LogD (pH = 5.5)
|
1.8247793
|
LogD (pH = 7.4)
|
3.361728
|
Log P
|
3.6093197
|
Molar Refractivity
|
109.1073 cm3
|
Polarizability
|
40.334778 Å3
|
Polar Surface Area
|
69.72 Å2
|
Rotatable Bonds
|
8
|
Lipinski's Rule of Five
|
false
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
S006
|
Biochem/physiol Actions Selective 5-HT2 serotonin receptor antagonist. Ketanserin significantly reduces nicotine self-administration in rats, supporting an unexpected involvement of serotonin in nicotine addiction.1 |
Sigma Aldrich -
15850
|
Biochem/physiol Actions Selective 5-HT2 serotonin receptor antagonist. Ketanserin significantly reduces nicotine self-administration in rats, supporting an unexpected involvement of serotonin in nicotine addiction.1 |
PATENTS
PATENTS
PubChem Patent
Google Patent